A Phase 1/2 interventional study of AG019 - Low Dose and Teplizumab in Diabetes type1, sponsored by Precigen Actobio T1D, LLC. Completed at 18 sites in 2 countries. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-02-01.
Sponsored by Precigen Actobio T1D, LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 7th largest by enrollment, is the only one that started in 2018, is the only one in phase 1/2, and was the 5th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Abdullah Kars · Sites in Turkey
Ages 18–45
By country, each count listing its studies:
teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2018.
This study's enrollment of 45 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This is the only study on the registry with Precigen Actobio T1D, LLC as lead sponsor.
Precigen Actobio T1D, LLC has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).
This Phase 1b/2a, multi-center study will be conducted in participants with clinical recent-onset type 1 diabetes (T1D).
The primary objective of this study is to assess the safety and tolerability of different doses of AG019 alone as well as AG019 in combination with teplizumab. The secondary objectives of this study are: to obtain pharmacodynamic (PD) data of AG019 alone as well as AG019 in combination with teplizumab; and to determine the potential presence of AG019 in systemic circulation (safety - systemic exposure) and the presence of L. lactis bacteria in fecal excretion (local exposure): Pharmacokinetic (PK) profile.
This study consists of 2 phases:
Phase 1b: this open-label part of the study will investigate the safety and tolerability of 2 different doses of AG019 in 2 age groups (18-40 years of age and 12-17 years of age).
Phase 2a: this randomized, double-blind part of the study will investigate the safety and tolerability of AG019, in combination with teplizumab, in 2 age groups (18-40 years of age and 12-17 years of age).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: AG019 - Low Dose
Biological: AG019 - High Dose
Biological: AG019 - Low Dose
Biological: AG019 - High Dose
Drug: Teplizumab · Drug: Placebo-AG019 · Drug: Placebo-Teplizumab · Biological: AG019 - High Dose
Drug: Teplizumab · Drug: Placebo-AG019 · Drug: Placebo-Teplizumab · Biological: AG019 - High Dose
Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
Formulated identically to AG019 with the active ingredient removed.
Formulated identically to teplizumab with the active ingredient removed.
Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
Solid, orally administered capsule - 6 capsules per day for 8 weeks.
Incidence of Treatment-emergent Adverse Events (TEAE)
Treatment-emergent adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary with AG019 alone or with teplizumab
Time frame: up to 6 months
AG019 in Systemic Circulation
The presence of live L. lactis bacteria in blood will be assessed by plating
Time frame: Up to 3 months after initiation of the treatment
L. Lactis-secreted hPINS or hIL-10 in Systemic Circulation
The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)
Time frame: Up to 3 months after initiation of the treatment
AG019 in Feces
The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)
Time frame: Up to 8 days after completion of the treatment
C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months
MMTT-stimulated 2-hour C-peptide AUC was defined as the mean area under the C-peptide level time curve over the 2-hour period divided by the duration after a mixed-meal tolerance test.
Time frame: up to 12 months
Incidence of Treatment Emergent Adverse Events up to 12 Months
Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.
Time frame: Up to 12 months from screening
AG019 monotherapy cohorts: a total of 8 single dose patients and 19 repeat dose patients. AG019/teplizumab combination cohorts: a total of 18 patients
| Milestone | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 5 | 2 | 5 | 2 | 4 | 2 | 5 | 10 | 2 | 5 | 1 |
| Completed | 2 | 5 | 2 | 4 | 2 | 4 | 2 | 4 | 10 | 2 | 4 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
Treatment-emergent adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary with AG019 alone or with teplizumab
| Events | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Treatment-emergent Adverse Events (TEAE) | 1 | 6 | 1 | 19 | 1 | 28 | 1 | 19 | 91 | 25 | 22 | 1 |
The presence of live L. lactis bacteria in blood will be assessed by plating
| Participants | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|
| AG019 in Systemic Circulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)
| Participants | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|
| L. Lactis-secreted hPINS or hIL-10 in Systemic Circulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)
| Participants | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|
| participants with AG019 in feces | 3 | 3 | 9 | 0 | 3 | 0 |
| participants with no AG019 in feces | 2 | 1 | 1 | 2 | 0 | 1 |
MMTT-stimulated 2-hour C-peptide AUC was defined as the mean area under the C-peptide level time curve over the 2-hour period divided by the duration after a mixed-meal tolerance test.
| nmol/L | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | AG019 Cohort 1 - Low (Repeat)-Dose/Adults | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents |
|---|---|---|---|---|---|---|---|---|
| C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months | 0.89 ± 0.61 | 0.57 ± 0.13 | 0.48 ± 0.19 | 0.73 ± 0.01 | 0.57 ± 0.21 | 0.25 ± 0 | 0.62 ± 0.48 | 0.78 ± 0.35 |
Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.
| events | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Treatment Emergent Adverse Events up to 12 Months | 1 | 8 | 1 | 26 | 1 | 33 | 1 | 26 | 97 | 26 | 23 | 2 |
Collected over Adverse events were collected from signature of informed consent until completion of the study (or premature withdrawal), an average of 13 months (1 month of screening plus 12 months of study participation).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG019 Cohort 1 - Low (Single) Dose/Adults | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| AG019 Cohort 1 - Low (Repeat) Dose/Adults | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| AG019 Cohort 2 - High (Single) Dose/Adults | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| AG019 Cohort 2 - High (Repeat) Dose/Adults | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| AG019 Cohort 3 - Low (Single) Dose/Adolescents | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| AG019 Cohort 4 - High (Single) Dose/Adolescents | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| AG019 Cohort 4 - High (Repeat) Dose/Adolescents | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Combination Cohort 1 - Active AG019/Teplizumab - Adults | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 0/2 | 0/5 | 0/10 | 2/2 | 0/5 | 0/1 |
| HeadacheNervous system disorders | 0/2 | 0/5 | 0/2 | 1/5 | 0/2 | 0/4 | 0/2 | 1/5 | 5/10 | 2/2 | 1/5 | 0/1 |
| AnxietyPsychiatric disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 0/2 | 1/5 | 1/10 | 0/2 | 1/5 | 1/1 |
| Attention deficit hyperactivity disorderPsychiatric disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 0/2 | 0/5 | 0/10 | 0/2 | 1/5 | 1/1 |
| Upper respiratory tract infectionInfections and infestations | 0/2 | 3/5 | 0/2 | 1/5 | 0/2 | 2/4 | 0/2 | 2/5 | 1/10 | 0/2 | 0/5 | 0/1 |
| LeukopeniaBlood and lymphatic system disorders | 0/2 | 0/5 | 0/2 | 1/5 | 0/2 | 2/4 | 0/2 | 2/5 | 2/10 | 0/2 | 0/5 | 0/1 |
| LymphadenopathyBlood and lymphatic system disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 2/4 | 0/2 | 0/5 | 1/10 | 0/2 | 0/5 | 0/1 |
| Sinus bradycardiaCardiac disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 1/2 | 0/5 | 0/10 | 0/2 | 0/5 | 0/1 |
| VertigoEar and labyrinth disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 0/2 | 0/5 | 0/10 | 1/2 | 0/5 | 0/1 |
| Abdominal discomfortGastrointestinal disorders | 0/2 | 0/5 | 0/2 | 0/5 | 0/2 | 0/4 | 0/2 | 0/5 | 0/10 | 1/2 | 0/5 | 0/1 |
| Age, Continuous(years) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 38.0 ± 5.7 | 26.0 ± 8.9 | 19.5 ± 2.1 | 22.0 ± 7.4 | 16.5 ± 0.7 | 14.0 ± 2.2 | 17.0 ± 0.0 | 14.0 ± 1.9 | 26.5 ± 6.7 | 29.0 ± 5.7 | 14.0 ± 1.1 | 12.0 ± 0.0 | 20.0 ± 8.6 |
| Sex: Female, Male(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 1 | 2 | 2 | 2 | 0 | 3 | 4 | 1 | 3 | 1 | 20 |
| Male | 2 | 4 | 1 | 3 | 0 | 2 | 2 | 2 | 6 | 1 | 2 | 0 | 25 |
| Ethnicity (NIH/OMB)(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Not Hispanic or Latino | 2 | 5 | 1 | 4 | 2 | 4 | 1 | 5 | 10 | 2 | 5 | 1 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline serological cytomegalovirus positivity(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 2 | 5 | 2 | 5 | 2 | 3 | 2 | 5 | 5 | 1 | 4 | 1 | 37 |
| Positive | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 5 | 1 | 0 | 0 | 7 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Baseline serological Epstein-Barr virus positivity(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 2 | 2 | 2 | 4 | 2 | 4 | 2 | 4 | 4 | 0 | 4 | 1 | 31 |
| Positive | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 6 | 2 | 1 | 0 | 14 |
| Autoantibody positivity - GAD65(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| Positive | 1 | 5 | 2 | 5 | 1 | 3 | 1 | 5 | 10 | 2 | 3 | 1 | 39 |
| Missing | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Autoantibody positivity - IA-2(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 1 | 2 | 1 | 1 | 0 | 2 | 0 | 2 | 5 | 1 | 1 | 0 | 16 |
| Positive | 0 | 2 | 1 | 4 | 1 | 2 | 0 | 2 | 3 | 1 | 4 | 1 | 21 |
| Missing | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 8 |
| Autoantibody positivity - ZnT8(Participants) | AG019 Cohort 1 - Low (Single) Dose/Adults | AG019 Cohort 1 - Low (Repeat) Dose/Adults | AG019 Cohort 2 - High (Single) Dose/Adults | AG019 Cohort 2 - High (Repeat) Dose/Adults | AG019 Cohort 3 - Low (Single) Dose/Adolescents | AG019 Cohort 3 - Low (Repeat) Dose/Adolescents | AG019 Cohort 4 - High (Single) Dose/Adolescents | AG019 Cohort 4 - High (Repeat) Dose/Adolescents | Combination Cohort 1 - Active AG019/Teplizumab - Adults | Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults | Combination Cohort 2 - Active AG019/Teplizumab - Adolescents | Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 7 |
| Positive | 1 | 2 | 1 | 2 | 0 | 3 | 0 | 3 | 5 | 0 | 3 | 0 | 20 |
| Missing | 1 | 3 | 0 | 1 | 2 | 0 | 2 | 1 | 3 | 2 | 2 | 1 | 18 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Oct 2021, 35 months.
Results were first posted in Feb 2023, 1 year 3 months after primary completion.
Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teplizumab